SYAB Stock Overview
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SYNLAB AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.00 |
| 52 Week High | €12.30 |
| 52 Week Low | €9.89 |
| Beta | 0.89 |
| 11 Month Change | -1.08% |
| 3 Month Change | -1.79% |
| 1 Year Change | 8.80% |
| 33 Year Change | -45.49% |
| 5 Year Change | n/a |
| Change since IPO | -39.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYAB | AT Healthcare | AT Market | |
|---|---|---|---|
| 7D | -0.4% | 1.6% | 0.6% |
| 1Y | 8.8% | 2.5% | 7.3% |
Return vs Industry: SYAB exceeded the Austrian Healthcare industry which returned 2.6% over the past year.
Return vs Market: SYAB exceeded the Austrian Market which returned 6.9% over the past year.
Price Volatility
| SYAB volatility | |
|---|---|
| SYAB Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 4.4% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 6.1% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: SYAB has not had significant price volatility in the past 3 months.
Volatility Over Time: SYAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 27,000 | Mathieu Floreani | www.synlab.com |
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.
SYNLAB AG Fundamentals Summary
| SYAB fundamental statistics | |
|---|---|
| Market cap | €2.42b |
| Earnings (TTM) | €89.35m |
| Revenue (TTM) | €2.62b |
27.1x
P/E Ratio0.9x
P/S RatioIs SYAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYAB income statement (TTM) | |
|---|---|
| Revenue | €2.62b |
| Cost of Revenue | €604.92m |
| Gross Profit | €2.01b |
| Other Expenses | €1.92b |
| Earnings | €89.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 76.87% |
| Net Profit Margin | 3.42% |
| Debt/Equity Ratio | 39.0% |
How did SYAB perform over the long term?
See historical performance and comparison